Immunoengineering: a credible mechanism for CAMPATH-1H action in bone marrow and organ transplantation and the implications for treatment of the immune dysfunction AIDS.
Immunoengineering is a term coined to represent the mostly future ability to use or target the immune system's natural components, with emphasis on the regulatory components, to up or down regulate the immune system's attack against specific proteins associated with an unwanted pathology or immune occurrence. It will constitute manipulating parts of the immune system, mostly those specific for the disease associated antigen(s) and generally of a regulatory nature, in various immunological locale or the whole body compartment, to achieve a disease free state for the patient. The number of practical applications awaiting the mastery of immune components as regulatory therapeutics is enormous and immunoengineering should provide treatments in a wide range of disease categories. HIV is a disease where this discipline could provide a quick cure, even eradication of the virus. A potential cheap solution to HIV infection, based on using immunoengineering and adaptable to the infrastructure problems of the Third World is highlighted in the following because of the health emergency that exists in the Third World.
Wendel
T D
TD
WThad@hotmail.com
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000628:therapy*; D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000502:physiology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000378:metabolism / Q000502:physiology* / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D015658:HIV Infections / Q000628:therapy; D006801:Humans; D007114:Immunization; D007167:Immunotherapy / Q000379:methods*; D008962:Models, Theoretical; D016377:Organ Transplantation; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab